MethylGene initiates phase 1/2 clinical trial to evaluate MGCD0103/Vidaza combination

By Angela McDaniels

Seattle, Nov. 14 - MethylGene Inc. said it has initiated the first of several phase 1/2 clinical trials that will evaluate a combination of MGCD0103 and Pharmion Corp.'s Vidaza (azacitidine) in patients with advanced myelodysplastic syndrome or acute myelogenous leukemia.

In the phase 1 portion of the trial, MGCD0103 will be given orally three times per week in combination with standard Vidaza treatment.

Key objectives of this portion of the study will be to evaluate the compatibility and safety of administering these two agents together and to determine the maximum dose of MGCD0103 that can safely be administered in this combination, the company said.

The phase 2 portion of the trial will determine the overall response rate.

The company expects to enroll up to 50 patients at five sites in North America.

MethylGene is a Montreal-based biopharmaceutical company focused on the development of therapeutics for cancer and infectious disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.